A deadly strain of malaria along the Thai-Cambodian border is becoming increasingly immune to treatment, threatening the global effort to end malaria, new evidence shows. Artemisinin combination therapy (ACT), whereby patients take both a fast-acting and slow-acting drug to kill the parasite, is losing its therapeutic effects as treatment is taking longer. The parasite's resistance to Artemisinin, one of two drugs in ACT therapy, is the driving factor behind the deterioration of ACT. (IRIN)
Get development's most important headlines in your inbox every day.
Thanks for subscribing!
